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OBJECTIVES This study noninvasively examined total creatine (CR) of the myocardium in dilated
cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM) using proton magnetic
resonance spectroscopy (1H-MRS).
BACKGROUND Abnormalities in CR metabolism in failing hearts have been reported. A biochemical study
suggested that myocardial metabolic changes are very similar in DCM and HCM despite the
different heart failure (HF) mechanisms.
METHODS Using cardiac-gated 1H-MRS with magnetic resonance image (MRI)-guided point-resolved
spectroscopy (PRESS) localization, we quantitatively measured septal CR. Patients with
either DCM (n  11) or HCM (n  7) and age-matched normal subjects (n  14) were
examined.
RESULTS Myocardial CR was significantly lower in DCM patients (16.1  4.5 mol/g wet weight
[range 10.2 to 22.9], p  0.05) than that in subjects with normal hearts (27.6  4.1 mol/g
[range 21.4 to 36.2]). Myocardial CR in HCM patients (22.6  8.1 mol/g [range 12.2 to
34.5]) was significantly lower than that in subjects with normal hearts (p  0.05) but was
significantly higher than that in DCM patients (p  0.05). In 18 patients with either DCM
or HCM, myocardial CR correlated positively with left ventricular ejection fraction (LVEF)
(y  0.22x  9.8, r  0.73, p  0.0006) but correlated negatively with plasma B-type
natriuretic peptide (BNP) levels (y  0.012x  22.4, r  0.54, p  0.022).
CONCLUSIONS This study showed that 1H-MRS can noninvasively detect CR depletion associated with the
severity of HF in cardiomyopathy. (J Am Coll Cardiol 2003;42:1587–93) © 2003 by the
American College of Cardiology Foundation
Abnormalities in creatine (CR) metabolism of the heart
(1–8) and other organs (9–11) in patients with failing hearts
have been demonstrated by 31P magnetic resonance spec-
troscopy (31P-MRS) or biochemical methods. It was dem-
onstrated by using 31P-MRS that the phosphocreatine
(PCr)-to-adenosine triphosphate (PCr/ATP) ratio is lower
in the failing human myocardium (1–3). In patients
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with dilated cardiomyopathy (DCM), this ratio correlated
well with the severity of heart failure (HF) estimated from
the New York Heart Association (NYHA) classification (3).
In patients with hypertrophic cardiomyopathy (HCM),
some studies indicated that myocardial PCr/ATP ratios are
lower than normal (4–7). We previously reported that
absolute concentrations of both myocardial PCr and ATP
were lower than normal in HCM patients, as determined by
31P-MRS (8). By biochemical methods, Kalsi et al. (12)
reported that the changes in myocardial energy metabolism
are very similar in biopsy specimens from DCM and HCM
patients before heart transplantation despite the different
HF mechanisms. The myocardial CR pool was reduced in
both HCM and DCM patients (12,13).
Recently, total CR was quantitatively measured in the
human heart by proton magnetic resonance spectroscopy
(1H-MRS). In patients with a myocardial infarction, Bot-
tomley and Weiss (14) demonstrated that myocardial CR
was decreased in nonviable infarcted regions using 1H-MRS
with stimulated-echo acquisition mode (STEAM) localiza-
tion.
In the present study, we measured the CR concentration
in the human myocardium by using 1H-MRS with point-
resolved spectroscopy (PRESS) localization, another
method of spatial localization (15). Using this method, we
examined the CR concentration in non-ischemic dysfunc-
tional hearts of DCM and HCM patients, which, to our
knowledge, has never been reported with the use of 1H-
MRS. We further assessed the left ventricular ejection
fraction (LVEF) and plasma B-type natriuretic peptide
(BNP) levels as indicators of HF severity.
METHODS
MRS study. The study protocol was approved by the
Ethical Committee of Shiga University of Medical Science.
The MRS studies were done with a GE 1.5-T Signa
imaging/spectroscopy system (General Electric Medical
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Systems, Milwaukee, Wisconsin). Subjects were examined
in the supine position. The Signa 1.5-T general-purpose
flex coil (GPFLEX, GE Medical Systems) was wrapped
around the chest so as to be centered over the heart.
Cardiac-gated spin-echo magnetic resonance imaging
(MRI) was performed to determine the location of localized
volume elements (voxels) for MRS investigation. Voxels
were localized to 8 cm3 (2  2  2 cm) in the interven-
tricular septum by the PRESS method (15). This voxel size
was chosen to yield suitable signal-to-noise ratios. The
PRESS flip angles were adjusted to achieve the maximum
intensity for the echo signal; therefore, the angles were set to
90° for the first pulse and 180° for the second and third
pulses. Automatic shimming was performed. The spectral
acquisition was gated once per two cardiac cycles using
plethysmography or electrocardiography. The acquisition
parameters included an echo time (TE) of 25 ms and a
repetition time (TR) of 1.4 to 2.9 s. At acquisition, the
initial data set of 16 signals was collected without water
suppression for the water resonance, and then a data set of
128 signals was collected with water suppression for the CR
resonance. A chemical shift-selective (CHESS) sequence
was used to suppress the water signal (16). The chemical
shift of water was taken as 4.75 ppm, as referred to in the
Signa Horizon LX PSD Manual. Spectral peaks were
identified with known chemical shifts: cholines at 3.2 ppm,
CR at 3.0 ppm, and lipids at 0.9 to 1.4 ppm (14,17).
Quantitative processing. Quantitation of CR spectra of
the myocardium was performed using water signals without
suppression as an internal concentration reference
(14,17,18). The integrated areas of the resonances of CR
and water were measured as reported previously in 31P-
MRS studies (8,19). Analysis was performed with a home-
built automatic data processing station, using the simplex
technique (20). Each peak was well fitted to an 80%
Gaussian and 20% Lorentzian line. All signal areas were
corrected for relaxation losses according to the following
formula (14,17):
S*N  SNFNEN [1]
FN  1/1  expTR/T1N]) [2]
EN  expTE/T2eN	 [3]
where SN is the total CR or water (W) magnetic resonance
signal area in the tissue; S*N is the corrected SN; EN and FN
are correction factors for effective spin-spin (T2e) and
spin-lattice (T1) relaxation effects, respectively; TR is the
pulse sequence repetition period; and TE is the echo time.
The T1 values of myocardial CR and W were estimated
using the spectra of five healthy volunteers acquired at TRs
of 1.5 and 6 s using PRESS without cardiac gating. The
obtained T1 values were 1.48  0.33 s and 1.21  0.33 s (n
 5) for CR and W, respectively. Spectral acquisition was
gated once per two cardiac cycles in this study: TR (s) 
120/heart rate (beats/min). Thus, FCR/FW is 1.09 when the
heart rate is 60 beats/min, where FCR and FW are T1
correction factors for CR and W, respectively, as defined in
the formula [2] (N  CR or W). The T2e values of
myocardial CR and W were obtained from the spectra of
five volunteers acquired at TEs of 25 to 45 ms. The
obtained T2e values were 135  13 ms and 33.1  6.1 ms
(n  5) for CR and W, respectively. Thus, the value of
ECR/EW is 0.565 at TE  25 ms, where ECR and EW are
T2e correction factors for CR and W, respectively, as
defined in the formula [3] (N  CR or W). The concen-
tration of total CR in tissue filling a voxel was calculated





The numbers “2” and “3” in the equation indicate the two
protons of water and the three protons of the N-methyl
group of CR, respectively. The concentration of water was
measured as 55.5 mol/l, and the myocardial tissue water
content was measured as 72.7% by weight (18,21). In
this study, therefore, the myocardial tissue water concen-
tration was calculated by the following equation:
Wmol/g	  0.727  55.5  1,000.
In 22 healthy volunteers (age 26 to 76 years), myocardial
CR contents were measured. There was no history sugges-
tive of cardiac or respiratory disease. They showed no
pathologic findings on the electrocardiogram and no car-
diomegaly on roentgenologic examination of the chest. The
acquisition time was 5 min per single examination when
the heart rate was 60 beats/min. The repeated CR exami-
nations yielded a coefficient of variation of 7.4% (n  8).
The correlation between age and myocardial CR concen-
tration was examined.
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CR  creatine
DCM  dilated cardiomyopathy
HCM  hypertrophic cardiomyopathy
HF  heart failure
1H- and 31P-MRS  proton and phosphorus-31
magnetic resonance spectroscopy,
respectively
LV  left ventricular
LVEF  left ventricular ejection fraction
MRI  magnetic resonance imaging
MRS  magnetic resonance spectroscopy/
spectroscopic
NML(1)  age-matched normal control group
NML(2)  non–age-matched larger normal
control group
NYHA  New York Heart Association
PCr  phosphocreatine
PRESS  point-resolved spectroscopy
STEAM  stimulated-echo acquisition mode
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Study group. Patients with idiopathic DCM (n  11) or
HCM (n  7) in NYHA functional class I, II, or III and 14
age-matched healthy volunteers [n  14, NML(1)] were
included in this study (Table 1). None of the patients
showed evidence of ischemia on the basis of coronary
arteriograms or thallium-201 stress imaging using a tread-
mill test. The average period between the detection of
disease and examination by MRS in DCM patients was 54
 58 months, whereas the average period in HCM patients
was 117  84 months. In HCM patients, four patients had
non-obstructive HCM, one patient had obstructive HCM,
and two patients with HCM at the dilated phase were
examined. Only one of the HCM patients had atrial
fibrillation when this study was performed. All the DCM
patients had a clinical history of severe HF (NYHA class
IV), whereas two of the HCM patients had a history of
NYHA class IV. The study involving 1H-MRS was not
performed in the acute phase of CHF, because of clinical
instability such as orthopnea. Thus, the MRS study was
performed when clinical stability was confirmed. The
NYHA functional class was determined when the MRS
study was performed. Of the 11 patients with DCM, 9
patients were treated with digitalis, 11 with diuretics, 10
with beta-blocker, 9 with angiotensin-converting enzyme
inhibitors, and two with an angiotensin II antagonist. Of
the seven HCM patients, four were treated with beta-
blocker, one with calcium antagonist, three with diuretics,
one with digitalis, one with an angiotensin-converting
enzyme inhibitor, and two with an angiotensin II antago-
nist. All the patients gave their written, informed consent
before the study.
BNP measurements in patients with DCM or HCM. In
the 18 patients with either DCM or HCM, the plasma
BNP levels were measured with a commercially available
specific immunoradiometric assay kit for human BNP
(Shionoria BNP kit, Shionogi, Osaka, Japan). Plasma BNP
was also measured on a day close to the MRS study, and
NYHA functional class in CHF patients at this time was
the same as that at the MRS study. Left ventricular (LV)
diastolic and systolic dimensions and LVEF were assessed
by ultrasonic echocardiography.
Data analysis. Data are expressed as the mean  SD.
Single comparisons were performed with the Student un-
paired t test. Multiple comparisons were performed by
one-way analysis of variance followed by the Fisher least
significant difference test. A p value 0.05 was considered
statistically significant.
RESULTS
MRS study in normal subjects. Representative data of
MRI-guided 1H-MRS obtained from a normal volunteer
are shown in Figure 1. We measured the myocardial CR in
22 healthy humans (age 26 to 76 years) by 1H-MRS
[NML(2)], non–age-matched larger normal control group).
The CR peak was observed at 3.03  0.08 ppm. As shown
in Figure 2, there was no significant correlation between age
and myocardial CR concentration. The mean myocardial
CR value was 28.9  4.4 mol/g in ages 40 years (n  9),
28.6  3.8 mol/g in ages 40 years (n  13), and 28.7 
4.0 mol/g in total (n  22).
MRS study in patients with DCM or HCM. Myocardial
CR concentrations measured by 1H-MRS was compared
among three age-matched groups: 11 patients with DCM,
seven patients with HCM, and 14 normal controls, age-
matched normal control group [NML(1)]. Fourteen age-
matched normal controls overlapped with the 22 normal
subjects in Figure 2. The clinical characteristics are summa-
rized in Table 1. There were no significant differences in
age, gender, body weight, and heart rate among the three
groups. The LV diastolic dimension was significantly
smaller in the HCM group (51.4  10.1 mm [range 41.0 to
66.0], p  0.01) than in the DCM group (69.2  10.2 mm
[range 56.0 to 87.0]), and the LV systolic dimension was
also significantly smaller in the patients with HCM (35.0 
13.1 mm [range 22.0 to 58.0], p  0.01) than in patients
with DCM (60.4  11.4 mm [range 46.0 to 77.0]). The
LVEF was significantly higher in patients with HCM (59.8
 20.2% [range 25.5 to 82.6%], p  0.01) than in the
patients with DCM (27.2  10.9% [range 15.4 to 43.9%]).
The representative 1H magnetic resonance spectrum ob-
tained from a patient with DCM is shown in Figure 3. The
representative spectrum from a patient with HCM is shown









Age (yrs) 51  13 55  21 52  11 45  13
Gender (M/F) 9/2 4/3 10/4 16/6
Body weight (kg) 61.1  17.3 58.3  7.6 62.2  9.5 60.8  8.8
Heart rate (beats/min) 68.8  12.5 59.6  10.9 60.6  9.8 59.4  8.9
NYHA functional class (n) II (6)/III (5) I (2)/II (2)/III (3) — —
LV diastolic dimension (mm) 69.2  10.2 51.4  10.1* — —
LV systolic dimension (mm) 60.4  11.4 35.0  13.1* — —
LV ejection fraction (%) 27.2  10.9 59.8  20.2* — —
Data are presented as the mean value  SD or number of subjects. *p  0.05 vs. DCM (the values obtained in DCM patients).
DCM  dilated cardiomyopathy; F  female; HCM  hypertrophic cardiomyopathy; LV  left ventricular; M  male;
NYHA  New York Heart Association.
1589JACC Vol. 42, No. 9, 2003 Nakae et al.
November 5, 2003:1587–93 Myocardial Creatine by 1H-MRS
in Figure 4, and further, the spectrum at the dilated phase
is shown in Figure 5. These spectra are shown at the same
scale relative to water (Figs. 1, 3, 4, and 5). The CR peaks
were observed at 3.01  0.03 ppm in the DCM group, 3.00
 0.03 ppm in the HCM group, and 3.02  0.06 ppm in
the NML(1) group. As shown in Figure 6, the myocardial
CR concentrations in DCM (16.1  4.5 mol/g wet
weight [range 10.2 to 22.9], p  0.05) were significantly
lower than those in the NML(1) group (27.6  4.1 mol/g
wet weight [range 21.4 to 36.2]). The CR values in the
NML(2) group are also shown in Figure 6. Myocardial CR
concentrations in patients with HCM (range 12.2 to 34.5)
ranged between those in NML(1) and those in the DCM.
Two cases of HCM at the dilated phase had lower values of
CR (12.2 and 15.6 mol/g), similar to the values found in
DCM, whereas two cases of asymptomatic HCM had
higher values of CR (28.0 and 34.5 mol/g), close to the
values found in the NML(1). Thus, myocardial CR in the
HCM group (22.6  8.1 mol/g wet weight) was signifi-
cantly lower than that in NML(1) (p  0.05) but was
significantly higher than that in the DCM group (p 
0.05). The two panels in Figure 7 show the relationship
between LVEF and myocardial CR concentration, and the
relationship between the plasma BNP level and myocardial
CR concentration in 18 patients with either DCM or
HCM. Mean plasma BNP levels in DCM and HCM
patients were 321  353 (n  11) and 320  259 pg/ml (n
 7), respectively. There was a positive correlation between
LVEF and myocardial CR (y  0.22x  9.8, r  0.73, p 
0.0006), but there was a negative correlation between
plasma BNP levels and myocardial CR (y  0.012x 
22.4, r  0.54, p  0.022). When the analysis was done
separately for the DCM and HCM groups, LVEF did not
significantly correlate with CR in the DCM group (p 
0.20); there was a borderline significance between LVEF
and CR in the HCM group (p  0.06); BNP did not
Figure 1. Spin-echo magnetic resonance imaging (A) and point-resolved
spectroscopy spectrum (B) in a 2  2  2-cm voxel in an intraventricular
septum (white box) of a 66-year-old healthy woman as a normal (NML)
volunteer. Total creatine resonance at 3.0 ppm (arrow). The creatine
concentration is 25.0 mol/g wet weight. Lipid resonance at 0.9 to 1.4
ppm.
Figure 2. Correlation between the age and the myocardial concentration of
total creatine (CR) in the 22 normal subjects.
Figure 3. Representative spin-echo magnetic resonance imaging (A) and
cardiac proton magnetic resonance spectrum (B) from a patient with
dilated cardiomyopathy (DCM) (a 45-year-old man). A low creatine peak
(3.0 ) (arrow) is observed in DCM (10.2 mol/g wet weight).
Figure 4. Representative spin-echo magnetic resonance imaging (A) and
cardiac proton magnetic resonance spectrum (B) from a patient with
obstructive hypertrophic cardiomyopathy (HCM) (case 1, 39-year-old
man). Diffuse hypertrophy of the left ventricular wall is observed, although
asymmetric septal hypertrophy was shown typically seven years before.
Myocardial creatine (3.0 ppm) (arrow) is well preserved in this case (24.7
mol/g wet weight).
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significantly correlate with CR in the DCM group (p 
0.11); but BNP correlated negatively (r  0.88, p  0.01)
with CR in the HCM group.
DISCUSSION
Our study demonstrated that myocardial CR was lower in
non-ischemic dysfunctional hearts with either DCM or
HCM than in ischemic dysfunctional hearts. Myocardial
CR concentrations correlated with the severity of HF
estimated from LVEF and plasma BNP levels: the more
severe the HF, the lower the CR concentration.
1H-MRS study in normal subjects. We measured myo-
cardial CR by cardiac-gated 1H-MRS with MRI-guided
PRESS localization. Formerly, it had been reported that
cardiac lipids and CR were observed by 1H-MRS with
PRESS localization (22). More recently, quantitative mea-
surements of CR in human hearts by 1H-MRS with
STEAM localization were reported (14). These values
obtained from 1H-MRS were confirmed by biochemical
measurements at biopsy (CR: 21.8  2.9 mol/g) in an
animal study (23). In our preliminary study, we obtained less
noisy spectroscopy with the PRESS method than with the
STEAM method. The CR signals were most clearly ob-
served in the septum, probably because they were not
influenced by the lipids in the epicardium or by the air in the
lung. Thus, we acquired CR signals by selected localization
of the septum using the PRESS method. Our CR value
measured in non-diseased myocardium (27.6 4.1 mol/g)
was in close agreement with the value (28  6 mol/g) in
a previous study by Bottomley and Weiss (14).
We examined the correlation between age and the myo-
cardial CR concentration in normal volunteers. In the age
range studied, the myocardial CR concentration did not
correlate significantly with age. Because the number of
healthy volunteers more than 65 years of age was small,
however, further examination may be needed to clarify the
influence of aging on the CR levels in human hearts (8,24).
Study limitations. In this study, voxels were localized to
2  2  2 cm in the interventricular septum. This size may
be larger than the wall thickness, especially in DCM
patients. Thus, this voxel may include the water of the blood
in the ventricle, which may cause CR values to be under-
estimated. However, spin-echo MRI showed no signal
intensity in the chamber. Similar to previous studies (14,23),
the integrated signal intensity in the large portion of the
PRESS voxel that intersects the blood-filled chamber was
small, owing to the “black blood” properties of the sequence.
Even if the voxel includes a blood space of 30% in total
volume, the underestimated CR value is 8%. This differ-
ence should not substantively affect our finding of low CR
levels in cardiomyopathy.
Furthermore, the T1 and T2e values were obtained in our
separate study of five healthy volunteers in the age range of
29 to 52 years. The corrections based on the T1 and T2e
values obtained from five healthy volunteers were applied to
all subjects including HF patients and higher aged people in
this study, although the T1 and T2e values may change with
aging or disease. Thus, these corrections may cause some
error in the patients and aging subjects. In addition, we
assumed that tissue water contents in the diseased hearts
were the same as those in healthy hearts.
1H-MRS study in cardiomyopathy. In our study, myocar-
dial CR in the patients with either DCM or HCM was
lower than in age-matched normal subjects [NML(1)]. The
CR concentration correlated positively with LVEF but
negatively with plasma BNP levels. A previous 31P-MRS
study revealed that the myocardial PCr/ATP ratio corre-
lated with the severity of HF estimated from the NYHA
class in DCM patients (3). Later, it was shown that the
PCr/ATP ratio correlated with LVEF in patients with
DCM (25). Thus, the myocardial PCr/ATP ratio in the
31P-MRS study and also the CR levels in the present study
were closely related to the severity of failing hearts.
Creatine metabolism is essential for normal cardiac func-
Figure 5. Representative spin-echo magnetic resonance imaging (A) and
cardiac proton magnetic resonance spectrum (B) from a patient with
hypertrophic cardiomyopathy (HCM) (case 2, 79-year-old woman). This
patient had already advanced to the dilated phase of HCM. A low creatine
peak (3.0 ppm) (arrow) is observed (15.6 mol/g wet weight).
Figure 6. Individual small plots show the total myocardial CR value
measured by proton magnetic resonance in the NML(1) group of controls
(open circles), patients in the DCM group (solid circles), and patients in
the HCM group (open squares). NML(1)  age-matched normal control
group; NML(2)  non–age-matched larger normal control group. Large
symbol and vertical bar  mean  SD. Myocardial CR was significantly
lower in the HCM group than in the NML(1) group. Myocardial CR in
the HCM group was significantly lower than that in NML(1) group but
was significantly higher than that in the DCM group. Abbreviations
defined in Figures 3 and 4.
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tion and viability. Creatine is transported against a concen-
tration gradient from the blood into the myocytes (26).
Adenosine triphosphate is the sole substrate for myofibrillar
ATPase and is absolutely required for muscle contraction.
The creatine kinase (CK) reaction is important for the rapid
resynthesis of ATP (27–29). Phosphoryl transfer from
PCr to adenosine diphosphate (ADP) is catalyzed by CK:
PCr  ADP  H º ATP  CR.
Nascimben et al. (30) examined human myocardium
samples and showed that the CR content and total CK
activity were both lower than normal in the failing myocar-
dium. A recent study showed that one mechanism of CR
depletion in DCM is caused by downregulating the
Na-CR co-transporter, which acts when CR is taken up
from the blood (13). The CR level measured by 1H-MRS
probably reflects the degree of myocardial cellular damage in
the diseased heart. A loss in CR results in a loss in PCr.
Using 31P-MRS, it was previously reported that myocardial
PCr/ATP was a predictor of total and cardiovascular mor-
tality in patients with DCM (31). In that study, 39 patients
with DCM were followed up for 2.5 years, and 8 of 20
patients with a low PCr/ATP ratio died, all from cardio-
vascular causes. Thus, the myocardial PCr/ATP ratio in the
31P-MRS study and also the CR levels in the 1H-MRS
study may provide important prognostic information on the
diseased heart.
In patients with HCM, myocardial CR concentrations
ranged between those in the NML groups and those in the
DCM group. Myocardial CR concentrations of the hyper-
trophic regions in two patients with asymptomatic HCM
were normal. In one case of obstructive HCM, myocardial
CR was well preserved. In this case, diffuse hypertrophy of
the LV wall (thickness 16 to 20 mm), including the outflow
tract, was observed; LVEF was 73%. Our study suggested
that the myocardial CR levels in HCM patients are well
preserved at the early stage of disease or when normal
contractile function is maintained while hypertrophy in-
creases. In two patients who had already advanced to the
dilated phase of HCM, however, myocardial CR concen-
trations had obviously decreased to a degree similar to that
in DCM patients. These cases exhibited typical symptoms
of HF, such as dyspnea on exertion, and had higher plasma
BNP values.
The mean value of CR was higher in the HCM group
than in the DCM group. Indeed, it is unclear whether this
difference is due to the difference in pathologic mechanisms
between DCM and HCM. When the present study was
performed, NYHA functional class and average values of
plasma BNP were similar between the DCM and HCM
groups. However, LVEF was higher in the HCM group.
All patients had a clinical history of NYHA class IV in the
DCM group, but only two patients had such a history in the
HCM group. Kalsi et al. (12) reported that myocardial
metabolic changes are very similar in biopsy specimens from
DCM and HCM patients (both NYHA class IV) despite
the different HF mechanisms. Thus, the difference in CR
concentrations between DCM and HCM patients appears
to be mainly due to the difference in the severity of HF.
31P-MRS and 1H-MRS. Recently, a combined 31P/1H-
MRS approach was attempted in the animal heart and
provided useful information (23). To date, it is difficult to
perform combined 31P and 1H-MRS in patients with HF,
because the total examination time required is over 2 h in
our laboratory. If combined 31P and 1H-MRS can be
applied to humans, however, we can obtain more detailed
information, which would be valuable in the elucidation of
pathologic mechanism(s) in diseased hearts.
Conclusions. Our results suggest that noninvasive mea-
surement of myocardial CR by 1H-MRS is useful in the
assessment of HF severity.
Figure 7. (Left panel) Correlation between total myocardial creatine (CR) concentrations and left ventricular ejection fraction (EF) in 18 patients with
either DCM (solid circles) or HCM (open squares). There was a positive correlation (r  0.73, p  0.0006) between the myocardial CR concentrations
and left ventricular EF. (Right panel) Correlation between myocardial CR concentrations and plasma B-type natriuretic peptide (BNP) levels in 18 patients
with either DCM or HCM. There was a negative correlation (r  0.54, p  0.022) between the myocardial CR concentrations and plasma BNP levels.
Other abbreviations defined in Figures 3 and 4.
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